About twenty years later, a new kind of polymer–protein conjugate named Adagen® (pegademase bovine) was first approved by FDA for enzyme replacement therapy against severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase [18,19]. The gene discussed is ADA; the disease is severe combined immunodeficiency.